Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TRVI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTrevi Therapeutics reports Q1 2026 financial results
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
medium
Company announced financial results for the quarter ended March 31, 2026 via press release. Detailed financial metrics are contained in the furnished exhibit rather than the filing body.
Item 2.02 verify on EDGAR → -
low
This is a routine quarterly earnings announcement with no unusual disclosures or material business events reported in the 8-K filing itself.
8-K: Earnings view on EDGAR →
Summary
Trevi Therapeutics filed an 8-K to announce its first quarter 2026 financial results for the period ending March 31, 2026. The announcement was made through a press release furnished as an exhibit to the filing. This is a standard quarterly earnings disclosure with no material business events or unusual items reported in the filing body itself.
The actual financial performance metrics, operational updates, and management commentary would be contained in the press release exhibit. Retail investors should review the furnished press release for specific revenue, expense, cash position, and pipeline development details. As a routine quarterly update, the key follow-on item to monitor is whether the company meets any guidance provided in the release and how the market responds to the reported results.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 5, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ended March 31, 2026.
The company disclosed its financial results for the first quarter of 2026 ending March 31, 2026. The actual financial details are contained in a press release furnished as an exhibit to this filing. This is a routine quarterly earnings announcement.
Event · Item 9.01 — Financial Statements and Exhibits
Trevi Therapeutics filed an 8-K to furnish a press release issued May 5, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press release issued by the Company on May 5, 2026
The company furnished a press release dated May 5, 2026 as Exhibit 99.1. The 8-K body does not describe the press release content, so the nature of the disclosure cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify